SEARCH

SEARCH BY CITATION

References

  • 1
    Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005; 11: 6370.
  • 2
    Westfall SD, Skinner MK. Inhibition of phosphatidylinositol3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. Mol Cancer Ther 2005; 4: 176471.
  • 3
    Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006; 6: 44958.
  • 4
    Dodier P, Piche A. Bcl-XL is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells. Gynecol Oncol 2006; 100: 25463.
  • 5
    Liu Z, Li H, Derouet M et al . Oncogenic ras inhibits anoikis of intestinal epithelial cells by preventing the release of a mitochondrial pro-apoptotic protein Omi/HtrA2 into the cytoplasm. J Biol Chem 2006; 281: 14 73847.
  • 6
    Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004; 430: 10349.
  • 7
    Haapasalo A, Sipola I, Larsson K et al . Regulation of TRKB surface expression by brain-derived neurotrophic factor and truncated TRKB isoforms. J Biol Chem 2002; 277: 43 1607.
  • 8
    Schramm A, Schulte JH, Astrahantseff K et al . Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett 2005; 228: 14353.
  • 9
    Satoh F, Mimata H, Nomura T et al . Autocrine expression of neurotrophins and their receptors in prostate cancer. Int J Urol 2001; 8: S2834.
  • 10
    Sclabas GM, Fujioka S, Schmidt C et al . Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res 2005; 11: 4409.
  • 11
    Yang ZF, Ho DW, Lam CT et al . Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma. Cancer Res 2005; 65: 21925.
  • 12
    Ricci A, Graziano P, Mariotta S et al . Neurotrophin system expression in human pulmonary carcinoid tumors. Growth Factors 2005; 23: 30312.
  • 13
    Bardelli A, Parsons DW, Silliman N et al . Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003; 300: 949.
  • 14
    Desmet CJ, Peeper DS. The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? Cell Mol Life Sci 2006; 63: 7559.
  • 15
    Li Z, Jaboin J, Dennis PA, Thiele CJ. Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death. Cancer Res 2005; 65: 20705.
  • 16
    Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6: 18492.
  • 17
    Schmidt M, Hovelmann S, Beckers TL. A novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosis. Br J Cancer 2002; 87: 92432.
  • 18
    Lee S, Choi EJ, Jin C, Kim DH. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 2005; 97: 2634.
  • 19
    Harnois C, Demers MJ, Bouchard V et al . Human intestinal epithelial crypt cell survival and death: Complex modulations of Bcl-2 homologs by Fak, PI3-K/Akt-1, MEK/Erk, and p38 signaling pathways. J Cell Physiol 2004; 198: 20922.
  • 20
    Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol3′-kinase increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 15: 108792.
  • 21
    Mabuchi S, Ohmichi M, Nishio Y et al . Inhibition of inhibitor of nuclear factor-κB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res 2004; 10: 764554.
  • 22
    Sain N, Krishnan B, Ormerod MG et al . Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther 2006; 5: 1197208.
  • 23
    Treeck O, Wackwitz B, Haus U, Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 2006; 102: 2929.
  • 24
    Frankel A, Rosen K, Filmus J, Kerbel RS. Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-XL. Cancer Res 2001; 61: 483741.
  • 25
    Cheng KW, Lahad JP, Kuo WL et al . The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 2004; 10: 12516.
  • 26
    Li X, Cao X, Li X, Zhang W, Feng Y. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer. Cancer Sci 2007; 98: 15926.
  • 27
    Sui G, Soohoo C, Affarel B et al . DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 551520.
  • 28
    Davidson B, Lazarovici P, Ezersky A et al . Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin Cancer Res 2001; 7: 345764.
  • 29
    Davidson B, Reich R, Lazarovici P et al . Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 2003; 9: 224859.
  • 30
    Spears N, Molinek MD, Robinson LL et al . The role of neurotrophin receptors in female germ-cell survival in mouse and human. Development 2003; 130: 548191.
  • 31
    Paredes A, Romero C, Dissen GA et al . TrkB receptors are required for follicular growth and oocyte survival in the mammalian ovary. Dev Biol 2004; 267: 43049.
  • 32
    Uttamsingh S, Zong CS, Wang LH. Matrix-independent activation of phosphatidylinositol3-kinase, Stat3, and cyclin A-associated Cdk2 is essential for anchorage-independent growth of v-Ros-transformed chicken embryo fibroblasts. J Biol Chem 2003; 278: 18 798810.
  • 33
    Rytomaa M, Lehmann K, Downward J. Matrix detachment induces caspase-dependent cytochrome c release from mitochondria: inhibition by PKB/Akt, but not Raf signaling. Oncogene 2000; 19: 44618.
  • 34
    Schulte JH, Schramm A, Klein-Hitpass L et al . Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. Oncogene 2005; 24: 16577.
  • 35
    Burgering BM, Coffer PJ. Protein kinase B (c-AKT) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995; 376: 599602.
  • 36
    Coltella N, Rasola A, Nano E et al . p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. Int J Cancer 2006; 118: 298190.
  • 37
    Zhou H, Li XM, Meinkoth J, Pittman RN. Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol 2000; 151: 48494.
  • 38
    Tsuruta F, Masuyanam N, Gotoh Y. The phosphatidylinositol3-kinase (PI3K)–Akt pathway suppresses Bax translocation to mitochondria. J Biol Chem 2000; 277: 14 0407.
  • 39
    Gao N, Flynn DC, Zhang Z et al . G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 2004; 287: C28191.
  • 40
    Yan X, Fraser M, Qiu Q, Tsang BK. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol 2006; 102: 34855.